Saturday 17 October 2026
Export CTSO’s income statement to Excel — free account
Cytosorbents Corporation
CTSO Healthcare Medical Devices
Cytosorbents Corporation’s revenue for fiscal 2025 (year ended December 2025) was $37.1 million, up 4.12% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 333.3%, free cash flow grew 64.9% and total debt rose 19.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
4.11
1.05
+34.31%
Follow CTSO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 4 | 2 | 2 | 5 | 3 | 4 | 5 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.07 | 1.39 | 1.54 | 2.29 | 4.21 | 7.55 | 4.98 | 11.03 | 11.94 | 15.08 |
Altman Z-Score |
(9.24) | (8.26) | (7.63) | (4.81) | 0.91 | 15.27 | (7.44) | 1.59 | (1.14) | (13.26) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(23.50) | (21.30) | (19.25) | (12.62) | (3.61) | 5.12 | (24.36) | (14.10) | (19.06) | (53.66) |
P/Operating CF |
(8.24) | (21.16) | (7.46) | (14.85) | (33.08) | (292.47) | (30.11) | (91.69) | (441.69) | (133.17) |
Beneish M-Score |
(2.11) | (3.06) | (3.30) | (2.08) | (2.48) | (2.27) | (2.95) | (2.51) | (2.38) | (4.37) |
P/B ratio |
6.74 | 4.46 | 2.03 | 2.24 | 2.90 | 3.91 | 36.33 | 14.66 | 17.62 | 107.44 |
Price to Tangible BV |
14.85 | 6.71 | 2.50 | 2.56 | 3.14 | 4.13 | 2,190.22 | 14.66 | 17.62 | 107.44 |
EV/Sales |
1.42 | 1.62 | 1.24 | 1.80 | 3.32 | 5.83 | 5.09 | 10.48 | 11.45 | 15.05 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(4.26) | (4.00) | (1.79) | (2.21) | (10.24) | (42.58) | (7.58) | (21.75) | (26.86) | (21.30) |
EV/FCF |
(4.12) | (3.83) | (1.71) | (1.79) | (7.84) | (32.79) | (6.95) | (19.08) | (21.32) | (19.57) |
Quick Ratio |
1.42 | 1.59 | 1.44 | 2.86 | 4.14 | 7.54 | 1.68 | 3.80 | 2.49 | 1.56 |
Current Ratio |
2.13 | 2.20 | 1.81 | 3.48 | 4.70 | 8.12 | 2.10 | 4.09 | 2.64 | 1.83 |
Net Debt/EBITDA |
(0.85) | (0.40) | 0.30 | 0.56 | 1.77 | 7.50 | (0.15) | 0.82 | 0.77 | 0.03 |
Debt/Assets |
37.72% | 29.54% | 9.52% | 8.08% | 15.44% | 1.14% | 54.97% | 29.07% | 41.46% | 50.67% |
Debt/Equity |
2.82 | 1.26 | 0.21 | 0.14 | 0.22 | 0.01 | 4.40 | 0.59 | 0.97 | 3.67 |
Asset Turnover |
0.81 | 0.71 | 0.54 | 0.45 | 0.48 | 0.70 | 0.81 | 0.77 | 0.90 | 0.91 |
Operating CF/Net income |
1.51 | 0.70 | 0.74 | 0.86 | 0.57 | 0.72 | 0.87 | 0.63 | 0.73 | 0.57 |
Capex/Depreciation |
(0.17) | (0.31) | (0.46) | (5.70) | (3.79) | (1.70) | (2.18) | (3.12) | (5.59) | (3.10) |
Interest Coverage |
(5.65) | (11.76) | — | (237.72) | (812.31) | — | — | — | — | — |
| (96.39%) | (119.80%) | (99.38%) | (67.00%) | (34.64%) | (18.97%) | (189.32%) | (126.57%) | (151.66%) | (246.41%) | |
| (17.91%) | (41.30%) | (50.34%) | (42.96%) | (27.37%) | (13.36%) | (62.57%) | (59.04%) | (52.05%) | (112.31%) | |
ROIC |
(56.48%) | (61.12%) | (138.73%) | (107.43%) | (58.59%) | (73.46%) | (190.11%) | (216.12%) | (209.74%) | (715.47%) |
Return on Tangible Assets |
(43.73%) | (99.70%) | (136.54%) | (94.32%) | (44.04%) | (10.53%) | (149.46%) | (74.58%) | (61.54%) | (285.54%) |
Average Days of Receivables |
74.35 | 75.06 | 71.12 | 59.61 | 38.25 | 45.93 | 65.35 | 63.95 | 53.14 | 54.92 |
Research and Development Expense of Revenue |
13.72% | 21.37% | 50.17% | 43.58% | 37.95% | 21.49% | 48.47% | 34.32% | 21.26% | 42.75% |
Selling, General and Administrative Expense of Revenue |
96.17% | 94.77% | 123.23% | 98.84% | 82.82% | 69.42% | 88.20% | 92.76% | 98.44% | 123.94% |
Intangible Assets out of Total Assets |
0.07 | 0.08 | 0.00 | 0.07 | 0.05 | 0.05 | 0.12 | 0.08 | 0.08 | 0.12 |
Share Based Compensation of Revenue |
7.46% | 10.56% | 13.37% | 10.95% | 14.37% | 11.48% | 11.38% | 23.93% | 26.43% | 33.46% |
Graham Net Nets |
(0.44) | (0.30) | (0.09) | 0.07 | 0.21 | 0.23 | (0.02) | 0.04 | 0.04 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(20.34%) | (41.76%) | (59.81%) | (41.61%) | (13.60%) | (2.51%) | (15.58%) | (6.93%) | (4.61%) | (7.89%) |
Free Cash Flow Yield |
(32.17%) | (30.48%) | (47.28%) | (43.74%) | (10.07%) | (2.36%) | (14.72%) | (4.98%) | (4.50%) | (5.10%) |
Revenue per Share |
11.91 | 13.08 | 13.92 | 15.92 | 19.91 | 21.13 | 15.47 | 14.65 | 10.97 | 7.49 |
Operating CF per Share |
(3.98) | (5.30) | (9.70) | (12.96) | (6.46) | (2.89) | (10.39) | (7.06) | (4.68) | (5.29) |
Capex per Share |
(0.13) | (0.25) | (0.42) | (2.96) | (1.97) | (0.86) | (0.94) | (0.99) | (1.22) | (0.47) |
Free Cash Flow per Share |
(4.11) | (5.55) | (10.12) | (15.92) | (8.43) | (3.76) | (11.33) | (8.05) | (5.89) | (5.76) |
Cash per Share |
2.01 | 3.04 | 6.33 | 10.16 | 24.05 | 36.80 | 7.58 | 14.56 | 12.55 | 4.12 |
Shareholders Equity per Share |
1.90 | 4.08 | 10.52 | 16.24 | 28.86 | 40.81 | 2.12 | 11.03 | 7.43 | 1.05 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.90 | 4.08 | 10.52 | 16.24 | 28.86 | 40.81 | 2.12 | 11.03 | 7.43 | 1.05 |
Free Cash Flow |
(12.79) | (15.10) | (22.59) | (34.69) | (18.29) | (7.29) | (18.28) | (12.36) | (8.14) | (7.33) |
Working Capital |
10.93 | 11.78 | 11.36 | 24.05 | 50.61 | 72.30 | 10.97 | 21.35 | 12.89 | 3.55 |
Capital Expenditures |
(0.41) | (0.67) | (0.94) | (6.46) | (4.28) | (1.68) | (1.52) | (1.52) | (1.68) | (0.60) |
Net Current Asset Value |
(17.64) | (14.66) | (4.08) | 5.90 | 37.36 | 71.72 | (3.06) | 11.00 | 6.90 | (0.53) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.02 | 0.03 | 0.19 | 0.10 | 0.04 | 0.06 | 0.07 | 0.11 | 0.06 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.31 | 0.24 | 0.20 | 0.11 | 0.22 | 0.46 | 0.36 | 0.28 | 0.21 | 0.34 |
Cash ROIC |
(44.39%) | (45.22%) | (52.96%) | (55.39%) | (14.23%) | (4.81%) | (59.54%) | (25.10%) | (21.66%) | (63.74%) |
Accounts Receivable Turnover |
4.98 | 5.32 | 5.30 | 6.81 | 8.92 | 8.52 | 5.93 | 7.32 | 8.33 | 9.15 |
Accounts Payable Turnover |
3.41 | 3.00 | 3.35 | 6.26 | 4.76 | 5.71 | 4.18 | 5.49 | 4.29 | 3.92 |
Inventory Turnover |
2.64 | 3.51 | 2.67 | 3.39 | 2.97 | 4.62 | 5.00 | 9.20 | 6.77 | 3.91 |
Average Days of Payables |
99.05 | 113.85 | 151.98 | 43.29 | 92.68 | 60.60 | 101.08 | 72.41 | 82.31 | 122.79 |
Days of Inventory on Hand |
182.33 | 93.16 | 134.93 | 90.53 | 157.47 | 88.30 | 104.78 | 40.60 | 52.63 | 76.99 |
Average Receivables |
7.44 | 6.69 | 5.86 | 5.09 | 4.84 | 4.81 | 4.21 | 3.07 | 1.82 | 1.04 |
Average Payables |
3.10 | 3.57 | 2.73 | 2.23 | 2.32 | 1.94 | 1.76 | 1.37 | 1.29 | 1.01 |
Average Inventory |
4.01 | 3.05 | 3.42 | 4.11 | 3.72 | 2.39 | 1.47 | 0.81 | 0.81 | 1.01 |
Average Assets |
45.78 | 50.16 | 58.09 | 76.38 | 89.73 | 58.67 | 30.79 | 29.15 | 16.90 | 10.47 |
Average Common Equity |
8.51 | 17.29 | 29.43 | 48.98 | 70.90 | 41.32 | 10.18 | 13.60 | 5.80 | 4.77 |
Columns are period end dates